307 results about "Tetralin" patented technology

The present invention provides a polysilazane-treating solvent which has excellent dissolving power and stability, has no influence on a substrate as an underlying layer and the properties of a polysilazane, is excellent in shape of cut edge, and further has high safety to the human body. The treating solvent comprises a solvent selected from the group consisting of tetralin, p-menthane, p-cymene, α-pinene, 1,8-cineol, and mixtures thereof, and a polysilazane treatment method using the same. This solvent may further comprise a solvent selected from the group consisting of aliphatic hydrocarbons, alicyclic hydrocarbons, and mixtures thereof.

The invention discloses a method for preparing ticagrelor, which comprises the following steps of by taking 1-[(3aR,4S,6R,6aS)-[[2,2- dimethyl-tetralin-4H-cyclopentadiene-1,3-dioxo heterocyclelane-4-oxygroup] ethyl acetate-6-base]-5-amidogen-4-formamido-1,2,3- triazole(II) as the raw material, sequentially carrying out cyclizing, replacement, condensation and reduction reactions, and removing the protecting group, so as to prepare the ticagrelor. The method is concise, environment-friendly and economic, has high chemical and chirality purity, and provides the new preparation method of ticagrelor industrialized production.

The invention provides a method for preparing cobalt-doped mesoporous alumina by taking a rubber latex as a biological template, and a method for catalytically oxidizing tetralin into tetralone under liquid phase. The invention relates to the method for preparing the cobalt-doped mesoporous alumina by taking the rubber latex as the template, and the method for synthesizing tetralone. The invention aims to develop a method which is used for preparing the cobalt-doped mesoporous alumina by taking the rubber latex as the biological template and a high-conversion and high-selectivity method which is used for catalytically oxidizing tetralin into tetralone under the liquid phase, and comprises the following steps: a mesoporous material is taken as a heterogeneous catalyst, and tetralin is catalytically oxidized into tetralone under the low temperature liquid phase. The experimental results show that the conversion rate of the tetralin reaches 80.3 percent and the selectivity of tetralone reaches 74.5 percent.

The invention discloses a novel synthesis method of palonosetron hydrochloride, which comprises that (1) (S)-tetralin formic acid is reacted with thionyl chloride and (S)-3-amido-quinine cyclic amine, to obtain (S, S)-quinuclidine tetralin formamide, (2), (S, S)-quinuclidine tetralin formamide is reacted with reductant and boron trifluoride diethyl etherate, to obtain (S, S)-tetralin methyl quinine cyclic amine, (3), (S, S)-tetralin methyl quinine cyclic amine is reacted with diphosgene to be added and reacted in boron trifluoride diethyl etherate solution, while the product is added and reacted with alcaine and water, to obtain palonosetron hydrochloride. And the synthesis route is represented as above: a: SOCI2, (S)-3-aminoquinuclidine, b: NaBH4, BF3OEt2, c: BF3OEt2, CICO2CCI3.

A novel oxygen-absorbing resin composition is not responsive to a metal detector, produces no odor after absorption of oxygen and has excellent oxygen-absorbing performance, and an oxygen-absorbing molded article, and a multilayer body, container, injection-molded article and medical container. Further provided are an oxygen-absorbing resin composition etc. having excellent oxygen-absorbing performance in a wide range of humidity conditions from low to high humidity. The oxygen-absorbing resin composition is an oxygen-absorbing resin composition containing a polyester compound and a transition metal catalyst, in which the polyester compound has at least one constituent unit having a tetralin ring. Furthermore, the oxygen-absorbing molded article of the present invention is formed by molding the oxygen-absorbing resin composition into a film form or a sheet form. Moreover, the multilayer body, container, injection-molded article, medical container, etc. of the present invention are obtained by using the oxygen-absorbing resin composition of the present invention.

The invention relates to a preparation method for obeticholic acid and an intermediate thereof. The intermediate 3alpha-hydroxy-6alpha-ethyl-7-keto-5beta-cholanic acid is obtained by subjecting 3alpha-hydroxy-6-ethylidene-7-keto-5beta-cholanic acid benzyl ester compounds to a reaction under the action of a catalyst and a hydrogen donor. The catalyst is selected from Pd/C or PtO2 or Raney Ni. The hydrogen donor is selected from cyclohexene or cyclohexadiene or tetrahydronaphthalene. According to the method, the yield is high, the stereoselectivity is high, safety is good, the reaction condition is mild, and the method is applicable to industrial production.

The invention discloses a preparation method of methyl phenyl hydrogen-containing silicone oil for LED packaging adhesive. The method takes methyl phenyl dimethoxy silaneas raw material and hydrochloric acid or acid cationic resin as catalyst, and performs hydrolytic condensation reaction under the heating and stirring condition, and prepares methyl phenyl hydroxyl silicone oil; the prepared methyl phenyl hydrogen-containing silicone oil and tetramethyl tetralin cyclotetrasiloxane (D4H) as raw materials, hexamethyl disiloxane (MM) or hydrogen-containing dual-sealing end (MMH) as the end-capping reagent, and acid cationic resin as the catalyst; the reaction is carried out under the heating and stirring conditions; after finishing the reaction, catalyst is filtered and removed; and then the methyl phenyl hydrogen-containing silicone oil is obtained after depressurizing and distilling the product and removing the low-boiling-point substance. The prepared hydrogen-containing silicone oil is colorless and transparent thick fluid; the light transmittance, refractive index and activated hydrogen content are high, the thermal stability is good; besides, the methyl phenyl hydrogen-containing silicone oil can be used as the LED packaging material.

The invention relates to new antitumor medicament compounds, namely tetralin amide compounds as shown in a general formula I or pharmaceutically acceptable salts thereof used as an antitumor medicament. The invention also provides a preparation method of the compounds and medicament compositions containing the compounds as well as in vitro and in vivo antitumor effect results and acute toxicity researches thereof. The antitumor medicament, namely tetralin amide compounds obtained by the preparation method, has better antitumor activity and safety, and can be applied to treatment of tumors such as leukemia, lung cancer, colon cancer, ovarian cancer, renal cancer and the like, thus the tetralin amide compounds have wide treatment ranges and also have extremely high application value in the medicine field as antitumor agents.

The invention discloses a preparation method of cisatracurium besylate. The method comprises the following steps: carrying out weal base dissociation on a R-tetrahydropapaverine-N-acetyl-L-leucine salt having a chiral purity of above 99.5% as a starting material so as to obtain R-tetrahydropapaverine; then carrying out a reaction on R-tetrahydropapaverine and 1,5-pentyl glycol diacrylate so as toobtain (1R,1'R)-2,2'-(3,11-dioxo-4,10-dioxa-1,13-subtridecyl) di[1,2,3,4-tetralin-6,7-dimethoxy-1-(3,4-dimethoxyl)benzyl]isoquinoline; after carrying out oxalate refinement and weal base dissociation, carrying out a reaction on (1R,1'R)-2,2'-(3,11-dioxo-4,10-dioxa-1,13-subtridecyl) di[1,2,3,4-tetralin-6,7-dimethoxy-1-(3,4-dimethoxyl)benzyl]isoquinoline and methyl benzenesulfonate so as to prepare1R,1'R-atracurium besilate; and finally, carrying out column chromatography separation on 1R,1'R-atracurium besilate so as to obtain cisatracurium besylate. By using the preparation method, the yieldof cisatracurium besylate can reach 30%, the purity of the product reaches above 98.6%, and single impurity content is below 0.3; and the process is brief, the yield is stable, and the product quality is good, thus the preparation method disclosed by the invention has an industrial application prospect.

The invention relates to a method for synthesizing Varenicline intermediate 2, 3, 4, 5-tetralin-1, 5-methylene-hydrogen-benzoazepine. The method includes the following steps: under the action of catalyst, mixing amyl nitrite with o-aminobenzoic acid solution to generate diazonium salt, then mixing the diazonium salt with cyclopentadiene, and heating to react to generate compound 1; feeding ozone into the solution of compound 1, after complete conversion, adding reducing agent to generate compound 2, then dripping the compound 2 to the mixed solution of triacetoxy sodium borohydride and benzylamine to generate compound 3 by loop closing; and hydrogenating the compound 3 under the action of palladium and carbon for debenzylation and reduction to obtain M intermediate 2, 3, 4, 5-tetralin-1, 5-methylene-hydrogen-benzoazepine. The method has the advantages of greatly simplifying the method for preparing Varenicline intermediate, being simple in production process and safe in operation, well ensuring no harm to the environment and control on production cost, increasing yield and being capable of becoming a process in great industrial production.

The invention relates to a crystal form of a diethanolamine salt of a thrombopoietin mimic and a preparation method thereof. Specifically, the invention relates to a type A crystal of (Z)-5-(2-hydroxy-3-(2-(3-methyl-5-oxo-1-(5,6,7,8-tetralin-2-yl)-1H-pyrazole-4(5H)-idene)hydrazino)phenyl)furan-2-diethanolamine carboxylate (a compound as shown in a formula (I)) and a preparation method thereof. The crystal has an x-ray powder diffraction pattern as shown in a figure 1. The type A crystal of the compound as shown in the formula (I) has good chemical stability and crystal-form stability, uses a crystallization solvent with low toxicity and low residues and can be better applied to clinical treatment.

A synthetic fuel formula using a blend of High Density Synthetic (HDS) (e.g. Decalin and Tetralin), and Low Density Synthetic (LDS) (e.g. Synthetic Paraffinic Kerosene—SPK) is disclosed. This HDS and LDS blend has been shown to be useful as a jet, rocket and diesel fuel of standard density, and under low temperature conditions. The inventions described herein relate to 100% synthetic hydrocarbon fuels derived from various carbonaceous materials such as, but not limited to, biomass, municipal waste, natural gas, and coal. This 100% synthetic fuel can be universally used for both jet and diesel fuels. It meets Joint Battlefield Use Fuel of the Future (J-BUFF), or Single Battlefield Fuel (SBF) strategic requirements. The commercial advantage of the present invention is that it can be prepared from commercial available fuel stocks or co-processed using currently available chemical processes.

The invention relates to a method for preparing an intermediate of axitinib and application of the intermediate in preparation of axitinib. The preparation method for the intermediate of axitinib 3-iodine-6-nitro-1-(teralin-2H-pyran-2-base)-1H-indazole comprises the following steps that 6-nitroindazole and 3,4-dihydro-2H-pyran react under the action of catalyst so as to protect perssad tetralin-2H-pyran-2-base at N-H site, and the key intermediate with high yield is obtained through iodination at site 3. The application of the intermediate in preparation of axitinib is as follows: Heck coupled reaction is carried out on the intermediate and 2-vinyl pyridine, then nitro reduction and diazo-reaction for iodination are sequentially carried out, finally, the axitinib is obtained after docking of 2-sulfydryl-N-methyl benzamide and deprotection. The related main initial raw materials are easy to purchase in markets, and the method has high yield and high molecule economic efficiency, is efficient and environment-friendly, and is suitable for industrial mass production.